MBody AI Ltd.
MBAIHealthcare|Biotechnology|CA
$2.41
-0.02 (-0.82%)
Tangible Book / Share
$3.04
Graham Number
$20.10
Cash / Share
$0.25
Financials
Financial Snapshot
Market Cap
$2.4M
Enterprise Value
$2.4M
Revenue (TTM)
—
Net Income (TTM)
—
Cash & Investments
—
Net Cash
—
Free Cash Flow (TTM)
—
Operating CF (TTM)
—
Debt/Equity
0.00
Income Statement
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $12.3M | $14.3M | $8.3M | $0.00 | $0.00 | |
| SG&A | $4.9M | $5.6M | $9.5M | $9.3M | $2.3M | |
| Operating Income | -$17.3M | -$20.0M | -$19.3M | -$25.9M | -$2.4M | |
| Interest Expense | $13.0K | $12.0K | $13.0K | $9.0K | $185.0K | |
| Pretax Income | -$17.2M | -$19.1M | -$17.6M | -$25.1M | $4.1M | |
| Net Income | -$17.2M | -$19.1M | -$17.6M | -$25.1M | $4.1M | |
| EPS (Diluted) | -21.21 | -23.59 | -21.00 | -30.10 | 4.62 | |
| EBITDA | -$17.0M | -$18.7M | -$17.3M | -$25.0M | $4.4M | |
| Shares Out. (M) | 0.81 | 0.81 | 0.84 | 0.84 | 0.89 |
Balance Sheet
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $26.5M | $4.1M | $8.8M | $0.00 | $2.0K | |
| Short-Term Investments | $25.1M | $37.6M | $15.9M | $265.0K | $217.0K | |
| Total Current Assets | $52.8M | $42.6M | $24.9M | $265.0K | $219.0K | |
| Total Assets | $55.7M | $45.4M | $25.0M | $377.0K | $7.5M | |
| Total Current Liabilities | $4.0M | $3.4M | $1.3M | $1.8M | $4.0M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $5.0M | $4.1M | $1.3M | $1.8M | $4.0M | |
| Stockholders' Equity | $50.7M | $41.3M | $23.7M | -$1.4M | $3.4M | |
| Retained Earnings | -$108.2M | -$127.3M | -$144.9M | -$170.0M | -$165.9M |
Cash Flow Statement
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -$16.3M | -$18.7M | -$17.0M | -$8.0M | -$46.0K | |
| Capital Expenditure | -$1.0M | -$486.0K | -$83.0K | $0.00 | $0.00 | |
| Free Cash Flow | -$17.3M | -$19.2M | -$17.0M | -$8.0M | -$46.0K | |
| Investing Cash Flow | -$16.0M | -$12.5M | $21.4M | -$840.0K | $48.0K | |
| Financing Cash Flow | $51.0M | $8.8M | $0.00 | $0.00 | $0.00 | |
| Issuance of Stock | $31.8M | $8.8M | $0.00 | $0.00 | $0.00 | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $491.0K | $879.0K | -$57.0K | $12.0K | $0.00 | |
| Net Change in Cash | $18.8M | -$22.4M | $4.4M | -$24.5M | -$46.0K |
Dilution Tracker
Shares Outstanding
1M
5-Year Share Growth
+9.9%
Stock Issuance (2025)
$0.00
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.81 | 0.81 | 0.84 | 0.84 | 0.89 | |
| Change vs Prior % | — | 0.0% | 3.1% | 0.0% | 6.6% | |
| Stock Issuance | $31.8M | $8.8M | $0.00 | $0.00 | $0.00 | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $491.0K | $879.0K | -$57.0K | $12.0K | $0.00 |
Margins & Profitability
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| ROE % | -33.9% | -46.3% | -74.2% | 1734.4% | 120.5% | |
| ROA % | -30.9% | -42.1% | -70.2% | -6670.8% | 55.3% | |
| ROIC % | -33.3% | -47.3% | -81.4% | 1974.8% | -68.7% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | -15.7% | 3.7% | -34.5% | 90.9% | |
| Net Income | 0.0% | -11.1% | 8.1% | -43.2% | 116.5% | |
| EPS (Diluted) | 0.0% | -11.2% | 11.0% | -43.3% | 115.3% | |
| Operating Cash Flow | 0.0% | -15.0% | 9.4% | 52.8% | 99.4% | |
| Free Cash Flow | 0.0% | -11.1% | 11.2% | 53.0% | 99.4% | |
| R&D Expense | 0.0% | 15.6% | -41.8% | -100.0% | 0.0% | |
| SG&A Expense | 0.0% | 14.4% | 67.6% | -1.7% | -74.9% | |
| Total Assets | 0.0% | -18.4% | -44.9% | -98.5% | 1885.7% | |
| Book Value / Share | 0.0% | -18.5% | -44.4% | -106.1% | 322.5% | |
| Debt | 0.0% | -15.8% | -100.0% | 0.0% | -88.2% | |
| Diluted Shares | 0.0% | 0.0% | 3.1% | 0.0% | 6.6% |
Valuation
P/E (TTM)0.52
P/S0.00
P/B0.62
10Y Low / Med / High0.15 / 0.33 / 2.94
EV/EBITDA0.56
10Y Low / Med / High0.06 / 1.04 / 2.32
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
Tangible Book / Share
$3.04
Graham Number
$20.10
Cash / Share
$0.25
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| P/E Ratio | -0.44 | -0.40 | -0.45 | -0.31 | 2.45 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 0.15 | 0.18 | 0.33 | -5.41 | 2.94 | |
| EV/EBITDA | 1.04 | -0.24 | 0.06 | -0.32 | 2.32 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $4.8M | $15.8M | $27.4M |
| Net Income | -$17.8K | $5.5M | $169.2K |
| EPS | $-0.02 | $6.14 | $0.19 |
| # Analysts (EPS) | 1 | 1 | 1 |